stockportfolio.pro
Boston Scientific Corporation (BSX)
Healthcare · Medical Devices · NYSE
Boston Scientific Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.08B | $9.05B | $9.82B | $10.73B | $9.91B | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B |
| Gross profit | $5.96B | $6.46B | $7.01B | $7.62B | $6.45B | $8.18B | $8.73B | $9.90B | $11.49B | $13.85B |
| Net income | $347.00M | $104.00M | $1.67B | $4.70B | $-82.00M | $1.04B | $642.00M | $1.57B | $1.85B | $2.90B |
| Net margin | 3.8% | 1.1% | 17.0% | 43.8% | -0.8% | 8.8% | 5.1% | 11.0% | 11.1% | 14.4% |
Source: Boston Scientific Corporation SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into BSX stock?
At today's market cap of $72.77B, Boston Scientific Corporation is priced for free-cash-flow growth of about 7.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $3.66B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 26.4%/yr over the last five fiscal years and revenue 15.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Boston Scientific Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BSX in your portfolio →
Boston Scientific Corporation financial history by metric
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific Corporation — frequently asked questions
What is Boston Scientific Corporation's revenue?
Boston Scientific Corporation (BSX) reported revenue of $20.07B for fiscal year 2025, up 19.9% from the prior year, according to its SEC filings.
Is Boston Scientific Corporation profitable?
Yes. BSX earned net income of $2.90B in fiscal 2025, a net margin of 14.4%.
What is BSX's P/E ratio?
Boston Scientific Corporation trades at a price-to-earnings ratio of about 20.5 based on the latest data in our nightly-refreshed cache.
How fast is Boston Scientific Corporation growing?
BSX's revenue grew at roughly 15.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Boston Scientific Corporation have?
As of fiscal year 2025, BSX carried roughly $299.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Boston Scientific Corporation's gross margin?
BSX's gross margin was 69.0% in fiscal 2025 — gross profit of $13.85B on revenue of $20.07B.
What is Boston Scientific Corporation's market cap?
Boston Scientific Corporation (BSX) has a market capitalization of about $72.77B, based on the latest data in our nightly-refreshed cache.
When does Boston Scientific Corporation's fiscal year end?
BSX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BSX stock?
At today's market cap of $72.77B, Boston Scientific Corporation is priced for free-cash-flow growth of about 7.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $3.66B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 26.4%/yr over the last five fiscal years and revenue 15.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Boston Scientific Corporation's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.